170018-97-0

Basic information

• Product Name: TERT-BUTYL 2-CYANOETHYLETHYLCARBAMATE
• Synonyms: TERT-BUTYL 2-CYANOETHYLETHYLCARBAMATE;(2-Cyanoethyl)ethyl-carbaMic Acid tert-Butyl Ester;tert-Butyl N-(2-cyanoethyl)-N-ethylcarbamate
• CAS NO: 170018-97-0
• Molecular Formula: C10H18N2O2
• Molecular Weight: 198.27
• Product Categories: Amines, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 170018-97-0.mol

Chemical Properties

• Boiling Point: 294.9±19.0 °C(Predicted)
• Appearance: /
• Density: 1.002±0.06 g/cm3(Predicted)
• PKA: -1.58±0.70(Predicted)
• CAS DataBase Reference: TERT-BUTYL 2-CYANOETHYLETHYLCARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 2-CYANOETHYLETHYLCARBAMATE(170018-97-0)
• EPA Substance Registry System: TERT-BUTYL 2-CYANOETHYLETHYLCARBAMATE(170018-97-0)

Safety Data

• Hazardous Substances Data: 170018-97-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 2-CYANOETHYLETHYLCARBAMATE is used as a reactant for the synthesis of aralkylamines, which serve as neuroprotectants. These neuroprotectants are crucial in the development of medications aimed at protecting the nervous system and treating various neurological disorders.
Used in Chemical Synthesis:
As a clear liquid chemical compound, TERT-BUTYL 2-CYANOETHYLETHYLCARBAMATE can also be utilized in other chemical synthesis processes, potentially leading to the creation of new compounds with various applications across different industries.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 21539-47-9 3-ethylamino propionitrile 

Downstream Products

• 273409-54-4 N-Ethyl-N-(3-aminopropyl)carbamic acid 1,1dimethylethyl ester 
• 1410042-58-8 2-[5-(3,4-difluorophenyl)-1,2,4-oxadiazol-3-yl]-N-ethylethanamine 
• 1410042-52-2 tert-butyl {2-[5-(3,4-difluorophenyl)-1,2,4-oxadiazol-3-yl]ethyl}ethylcarbamate 

Relevant articles and documents

HETEROAROMATIC RING DERIVATIVE

The compound represented by formula (IA) or a pharmaceutically acceptable salt thereof is based on orexin (OX) receptor antagonist activity, is useful in the treatment and prevention of illnesses including sleep disorder, depression, anxiety disorder, pan

Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments

The present invention relates to a synergetistic composition comprising one or more benzoazine-mono-N-oxides, and one or more benzoazine 1,4 dioxides for use in cancer therapy. The invention also provides a range of novel 1,2,4 benzoazine-mono-N-oxides and related analogues. These can be used as potentiators of the cytotoxicity of existing anticancer drugs and therapies for cancer treatment.

Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments

The present invention relates to a synergetistic composition comprising one or more benzoazine-mono-N-oxides, and one or more benzoazine 1,4 dioxides for use in cancer therapy. The invention also provides a range of novel 1,2,4 benzoazine-mono-N-oxides and related analogues. These can be used as potentiators of the cytotoxicity of existing anticancer drugs and therapies for cancer treatment.